The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Immunogenicity of aggregates of recombinant human growth hormone in mouse models
Open accessOverview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Effects of protein aggregates: An immunologic perspective
Rosenberg, A. S. (2006) · The AAPS Journal · doi:10.1208/aapsj080359 · Cited by 1,355
Protein secondary structures in water from second-derivative amide I infrared spectra
Dong, A., Huang, P., & Caughey, W. S. (1990) · Biochemistry · doi:10.1021/bi00465a022 · Cited by 1,333
Circulating interferon-α levels and hypertriglyceridemia in the acquired immunodeficiency syndrome.
Grunfeld, C., Kotler, D. P., Shigenaga, J. K., Doerrler, W., Tierney, A., Wang, J., Pierson, R. N., & Feingold, K. R. (1991) · The American Journal of Medicine · doi:10.1016/0002-9343(91)90536-7 · Cited by 286
Research works printed but not linked: 58
- Chi, 2003, Physical stability of proteins in aqueous solution: Mechanism and driving forces in nonnative protein aggregation, Pharm Res, 20, 1325, 10.1023/A:1025771421906 · DOI · Paper page
- Braun, 1997, Protein aggregates seem to play a key role among the parameters influencing the antigenicity of interferon alpha (IFN-alpha) in normal and transgenic mice, Pharm Res, 14, 1472, 10.1023/A:1012193326789 · DOI · Paper page
- Schellekens, 2003, The immunogenicity of biopharmaceuticals, Neurology, 61, S11, 10.1212/01.WNL.0000092358.51502.C0 · doi:10.1212/01.wnl.0000092358.51502.c0
- Wang, 2003, Correlation of rFVIII inactivation with aggregation in solution, Pharm Res, 20, 693, 10.1023/A:1023271405005 · DOI
- Moore, 1980, Role of aggregated human growth-hormone (Hgh) in development of antibodies to Hgh, J Clin Endocrinol Metab, 51, 691, 10.1210/jcem-51-4-691 · DOI · Paper page
- Ratner, 1990, Persistent cutaneous insulin allergy resulting from high-molecular-weight insulin aggregates, Diabetes, 39, 728, 10.2337/diab.39.6.728 · DOI
- Porter, 2001, Human immune response to recombinant human proteins, J Pharm Sci, 90, 1, 10.1002/1520-6017(200101)90:1<1::AID-JPS1>3.0.CO;2-K · DOI
- Barandun, 1962, Intravenous administration of human gamma-globulin, Vox Sanguinis, 7, 157, 10.1111/j.1423-0410.1962.tb03240.x · DOI · Paper page
- Ellis, 1969, Adverse reactions following administration of human gamma globulin, J Allergy, 43, 45, 10.1016/0021-8707(69)90019-7 · DOI
- Schellekens, 2002, Bioequivalence and the immunogenicity of biopharmaceuticals, Nat Rev Drug Discov, 1, 457, 10.1038/nrd818 · DOI · Paper page
- Gershon, 2002, Pure red-cell aplasia and recombinant erythropoietin, N Engl J Med, 346, 1584, 10.1056/NEJM200205163462015 · DOI
- Casadevall, 2002, Pure red-cell aplasia and antierythropoietin antibodies in patients treated with recombinant erythropoietin, N Engl J Med, 346, 469, 10.1056/NEJMoa011931 · DOI · Paper page
- Sluzky, 1991, Kinetics of insulin aggregation in aqueous-solutions upon agitation in the presence of hydrophobic surfaces, Proc Natl Acad Sci USA, 88, 9377, 10.1073/pnas.88.21.9377 · DOI · Paper page
- Rathore, 2008, Current perspectives on stability of protein drug products during formulation, fill and finish operations, Biotechnol Prog, 24, 504, 10.1021/bp070462h · DOI · Paper page
- Seefeldt, 2007, Specific volume and adiabatic compressibility measurements of native and aggregated recombinant human interleukin-1 receptor antagonist: Density differences enable pressure-modulated refolding, Biotechnol Bioeng, 98, 476, 10.1002/bit.21398 · DOI
- Purohit, 2006, Influence of aggregation on immunogenicity of recombinant human factor VIII in hemophilia A mice, J Pharm Sci, 95, 358, 10.1002/jps.20529 · DOI
- Hermeling, 2005, Structural characterization and immunogenicity in wild-type and immune tolerant mice of degraded recombinant human interferon alpha2b, Pharm Res, 22, 1997, 10.1007/s11095-005-8177-9 · DOI
- Hermeling, 2006, Antibody response to aggregated human interferon alpha2b in wild-type and transgenic immune tolerant mice depends on type and level of aggregation, J Pharm Sci, 95, 1084, 10.1002/jps.20599 · DOI · Paper page
- St John, 1999, High pressure fosters protein refolding from aggregates at high concentrations, Proc Natl Acad Sci USA, 96, 13029, 10.1073/pnas.96.23.13029 · DOI · Paper page
- St John, 2001, High pressure refolding of recombinant human growth hormone from insoluble aggregates—Structural transformations, kinetic barriers, and energetics, J Biol Chem, 276, 46856, 10.1074/jbc.M107671200 · DOI
- Bugelski, 2004, Predictive power of preclinical studies of recombinant therapeutic proteins in animals for the immunogenicity humans, Curr Opin Mol Therap, 6, 10
- Babiuk, 2004, Aggregate content influences the Thl/Th2 immune response to influenza vaccine: Evidence from a mouse model, J Med Virol, 72, 138, 10.1002/jmv.10540 · DOI
- Hermeling, 2005, Development of a transgenic mouse model immune tolerant for human interferon beta, Pharm Res, 22, 847, 10.1007/s11095-005-4578-z · DOI
- Adkins, 2000, Exclusive Th2 primary effector function in spleens but mixed Th1/Th2 function in lymph nodes of murine neonates, J Immunol, 164, 2347, 10.4049/jimmunol.164.5.2347 · doi:10.4049/jimmunol.164.5.2347
- Adkins, 1999, T-cell function in newborn mice and humans, Immunol Today, 20, 330, 10.1016/S0167-5699(99)01473-5 · DOI · Paper page
- Singh, 1996, Neonatal peptide exposure can prime T cells and, upon subsequent immunization, induce their immune deviation: Implications for antibody vs T cell-mediated autoimmunity, J Exp Med, 183, 1613, 10.1084/jem.183.4.1613 · DOI
- Petersen, 2006, Persistence of neutralizing antibodies after discontinuation of IFN beta therapy in patients with relapsing-remitting multiple sclerosis, Mult Scler, 12, 247, 10.1191/135248505ms1324oa · DOI
- Schellekens, 2004, Immunogenicity of recombinant human proteins: Causes and consequences, J Neurol, 251, 4, 10.1007/s00415-004-1202-9 · DOI · Paper page
- Polman, 2006, Neutralizing antibodies to interferon-beta may persist after cessation of therapy: What impact could they have?, Mult Scler, 12, 245, 10.1191/135248506ms1284ed · doi:10.1191/135248506ms1284ed
- Cleland, 1997, Recombinant human growth hormone poly(lactic-co-glycolic acid) microsphere formulation development, Adv Drug Deliv Rev, 28, 71, 10.1016/S0169-409X(97)00051-3 · DOI
- Whitmore, 2004, DICHROWEB, an online server for protein secondary structure analyses from circular dichroism spectroscopic data, Nucleic Acids Res, 32, W668, 10.1093/nar/gkh371 · DOI · Paper page
- Maa, 1996, Aggregation of recombinant human growth hormone induced by phenolic compounds, Int J Pharm, 140, 155, 10.1016/0378-5173(96)04577-2 · DOI
- Kueltzo, 2003, Derivative absorbance spectroscopy and protein phase diagrams as tools for comprehensive protein characterization: A bGCSF case study, J Pharm Sci, 92, 1805, 10.1002/jps.10439 · doi:10.1002/jps.10439
- Mach, 1994, Simultaneous monitoring of the environment of tryptophan, tyrosine, and phenylalanine residues in proteins by near-ultraviolet 2nd-derivative spectroscopy, Anal Biochem, 222, 323, 10.1006/abio.1994.1499 · DOI
- Galanaud, 1976, 2 processes for B-cell triggering by T-independent antigens as evidenced by effect of azathioprine, Cell Immunol, 22, 83, 10.1016/0008-8749(76)90009-5 · doi:10.1016/0008-8749(76)90009-5
- Dintzis, 1976, Molecular determinants of immunogenicity—Immunon model of immune-response, Proc Natl Acad Sci USA, 73, 3671, 10.1073/pnas.73.10.3671 · DOI · Paper page
- Yang, 2005, B lymphocyte activation by human papillomavirus-like particles directly induces Ig class switch recombination via TLR4-MyD88, J Immunol, 174, 7912, 10.4049/jimmunol.174.12.7912 · DOI
- Bachmann, 1993, The influence of antigen organization on B-cell responsiveness, Science, 262, 1448, 10.1126/science.8248784 · DOI · Paper page
- De Groot, 2007, Immunogenicity of protein therapeutics, Trends Immunol, 28, 482, 10.1016/j.it.2007.07.011 · DOI · Paper page
- Friede, 2005, Need for new vaccine formulations and potential of particulate antigen and DNA delivery systems, Adv Drug Deliv Rev, 57, 325, 10.1016/j.addr.2004.10.001 · DOI
- Bristow, 2001, The second international standard for somatropin (recombinant DNA-derived human growth hormone): Preparation and calibration in an international collaborative study, Biologicals, 29, 97, 10.1006/biol.2001.0281 · doi:10.1006/biol.2001.0281
- Hepner, 2006, Massspectrometrical analysis of recombinant human growth hormone Norditropin (R) reveals amino acid exchange at M14_V14 rhGH, Proteomics, 6, 775, 10.1002/pmic.200500334 · DOI
- Strasburger, 1990, Antigenic epitope mapping of the human growth-hormone molecule—A strategy to standardize growth-hormone immunoassays, Acta Paediatrica Scandinavica, 370, 82, 10.1111/j.1651-2227.1990.tb11679.x · doi:10.1111/j.1651-2227.1990.tb11679.x
- Nakashima, 1975, Adjuvant action of capsular polysaccharide of klebsiella-pneumoniae on antibody-response. 4. Roles of antigen and adjuvant for induction of primary and secondary antibody-responses and for development of immunological memory to bovine serum-albumin, Jpn J Microbiol, 19, 277, 10.1111/j.1348-0421.1975.tb00881.x · doi:10.1111/j.1348-0421.1975.tb00881.x
- Gammon, 1986, Induction of tolerance to one determinant on a synthetic peptide does not affect the response to a 2nd linked determinant—Implications for the mechanism of neonatal tolerance induction, J Exp Med, 164, 667, 10.1084/jem.164.2.667 · doi:10.1084/jem.164.2.667
- Clayton, 1989, Peptide-specific prevention of experimental allergic encephalomyelitis—Neonatal tolerance induced to the dominant T-cell determinant of myelin basic-protein, J Exp Med, 169, 1681, 10.1084/jem.169.5.1681 · DOI
- Billingham, 1953, Actively acquired tolerance of foreign cells, Nature, 172, 603, 10.1038/172603a0 · DOI · Paper page
- Gammon, 1986, Neonatal T-cell tolerance to minimal immunogenic peptides is caused by clonal inactivation, Nature, 319, 413, 10.1038/319413a0 · doi:10.1038/319413a0
- Duclos, 1977, Suppressor T cells—Presence in mice rendered tolerant by neonatal treatment with anti-receptor antibody or antigen, J Immunol, 119, 1769, 10.4049/jimmunol.119.5.1769 · doi:10.4049/jimmunol.119.5.1769
- Maverakis, 2000, J Exp Med, 191, 695, 10.1084/jem.191.4.695 · doi:10.1084/jem.191.4.695
- Forsthuber, 1996, Induction of T(H)1 and T(H)2 immunity in neonatal mice, Science, 271, 1728, 10.1126/science.271.5256.1728 · DOI · Paper page
- Adkins, 2001, The generation of Th memory in neonates versus adults: Prolonged primary Th2 effector function and impaired development of Th1 memory effector function in murine neonates, J Immunol, 166, 918, 10.4049/jimmunol.166.2.918 · DOI
- Klitgaard, 2006, Reduced susceptibility of recombinant polyclonal antibodies to inhibitory anti-variable domain antibody responses, J Immunol, 177, 3782, 10.4049/jimmunol.177.6.3782 · DOI
- Saban, 1996, Erythroid-specific expression of human growth hormone affects bone morphology in transgenic mice, Bone, 18, 47, 10.1016/8756-3282(95)00419-X · DOI
- Rosenberg, 2004, A risk-based approach to immunogenicity concerns of therapeutic protein products. Part 1. Considering consequences of the immune response to a protein, Biopharm Int, 17, 22
- Thavasu, 1992, Measuring cytokine levels in blood—Importance of anticoagulants, processing, and storage-conditions, J Immunol Methods, 153, 115, 10.1016/0022-1759(92)90313-I · DOI · Paper page
- Casanueva, 1992, Physiology of growth-hormone secretion and action, Endocrinol Metab Clin N Am, 21, 483, 10.1016/S0889-8529(18)30199-3 · DOI · Paper page
- VanCauter, 1996, Physiology of growth hormone secretion during sleep, J Pediatr, 128, S32, 10.1016/S0022-3476(96)70008-2 · DOI · Paper page
Cited by
Immunogenicity of therapeutic proteins: Influence of aggregation
Ratanji, K. D., Derrick, J. P., Dearman, R. J., & Kimber, I. (2014) · Journal of Immunotoxicology · doi:10.3109/1547691x.2013.821564 · Cited by 589
Immunogenicity of Therapeutic Protein Aggregates
Moussa, E. M., Panchal, J. P., Moorthy, B. S., Blum, J. S., Joubert, M. K., Narhi, L. O., & Topp, E. M. (2016) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2015.11.002 · Cited by 529
Impact of Product-Related Factors on Immunogenicity of Biotherapeutics
Singh, S. K. (2011) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.22276 · Cited by 350
Singh, S. K., Afonina, N., Awwad, M., Bechtold-Peters, K., Blue, J. T., Chou, D., Cromwell, M., Krause, H.-J., Mahler, H.-C., Meyer, B. K., et al. (2010) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.22097 · Cited by 334
Classification and Characterization of Therapeutic Antibody Aggregates
Joubert, M. K., Luo, Q., Nashed-Samuel, Y., Wypych, J., & Narhi, L. O. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.160457 · Cited by 316
Metadata
- Authors
- Fradkin, A. H., Carpenter, J. F., & Randolph, T. W.
- Venue
- Journal of Pharmaceutical Sciences
- Publisher
- Elsevier BV
- Published
- 2009-09
- Volume
- 98
- Issue
- 9
- Pages
- 3247-3264
- ISSN
- 0022-3549 (ISSN-L)
- OpenAlex
- W1969652074
- Cited by
- 170
- References
- 3
- FWCI
- 7.20
- Type
- journal article
- Language
- en
- Open access
- bronze
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Immunogenicity of aggregates of recombinant human growth hormone in mouse models. https://app.cochat.ai/papers/10.1002/jps.21834
- The paper
- Fradkin, A. H., Carpenter, J. F., & Randolph, T. W. (2009). Immunogenicity of aggregates of recombinant human growth hormone in mouse models. Journal of Pharmaceutical Sciences. https://doi.org/10.1002/jps.21834
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.